EBOLA: IMPACT AND RESPONSE

EBOLA

Published

2019-12-31

DOI:

https://doi.org/10.47203/IJCH.2019.v31i04.001

Keywords:

EBOLA, NEW EBOLA VACCINE

Dimensions Badge

Issue

Section

Editorial

Authors

Abstract

Ebola virus disease (EVD) is a severe illness caused by  Ebola viruses affecting man and non human primates.  This Ebola hemorrhagic fever (EHF) or simply Ebola, is often deadly in nature. The virus is transmitted to man from wild animals such as fruit bats. It is thought that fruit bats of the Pteropodidae family are natural Ebola virus host and act as normal carrier in nature. The WHO affirmed the EVD outbreak as a “Public Health Emergency of International Concern” on August 8th, 2014. EVD is manifested by fever, fatigue, muscle, pain, headache, and sore throat. There is no proven treatment for Ebola. Simple interventions can significantly improve chances of survival. Supportive treatment includes rehydration with fluids and body salts.. EVD has a risk of death in those infected, between 25% and 90%. Rapid geographic dissemination, nonspecific clinical presentation, lack of vaccine, and specific diagnostic test are the possible challenges to combat this dreaded public health menace. Hand hygiene is the most effective way to prevent the spread of the Ebola virus. Ebola vaccine candidates against Ebola have been developed in the decade prior to 2014, but none have yet been approved for clinical use in humans. Most recently, the European Medicines Agency (EMA) has approved the first ever Ebola vaccine (rVSV-ZEBOV-GP vaccine). This development has been appreciated from all the corners as it is in the interest of mankind and will always be considered as an important milestone in the field of public health.

 

How to Cite

1.
Alsabaani AA, Muzammil K, Mahmood SE. EBOLA: IMPACT AND RESPONSE : EBOLA. Indian J Community Health [Internet]. 2019 Dec. 31 [cited 2022 Sep. 30];31(4):428-30. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/1282

Downloads

Download data is not yet available.

Author Biographies

Abdullah A. Alsabaani, KING KHALID UNIVERSITY

1 Dr. Abdullah A. Alsabaani

Assistant Professor, Department of Family & Community Medicine, College of Medicine.

Dean, College of Applied Medical Sciences - Khamis Mushait Campus.

Director, Health Research Consultancy Office, Research and Consulting Studies Institute.

Director, Saudi Board of Preventive Medicine - Aseer Residency Program, SCFHS.

King Khalid University, Abha, Kingdom of Saudi Arabia

ORCID ID   https://orcid.org/0000-0003-2352-8249

Syed Esam Mahmood, KING KHALID UNIVERSITY

3 Dr. Syed Esam Mahmood

Professor, Department of Family & Community Medicine, College of Medicine,

King Khalid University, Abha, Kingdom of Saudi Arabia.

ORCID ID   https://orcid.org/0000-0001-5264-5677

References

"Ebola virus disease" (Press release). World Health Organization (WHO). 12 February 2018.

Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med. 2015 Jun 18;372(25):2423-7. doi: 10.1056/NEJMoa1500306. Epub 2015 May 7. PubMed PMID: 25950269; PubMed Central PMCID: PMC4547451.[PubMed]

"Recommendations for Breastfeeding/Infant Feeding in the Context of Ebola". Centers for Disease Control and Prevention (CDC). 19 September 2014. Archived from the original on 24 October 2014. Retrieved 26 October 2014.

Sprecher A. Handle Survivors with Care. N Engl J Med. 2017 Oct 12;377(15):1480-1482. doi: 10.1056/NEJMe1512928. Epub 2015 Oct 14. PubMed PMID: 26465064.[PubMed]

Available on https://www.who.int/emergencies/diseases/ebola/drc-2019 Last accessed on 19th November 2019.

Dovih P, Laing ED, Chen Y, Low DHW, Ansil BR, et al. Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover. Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover. PLOS Neglected Tropical Diseases 2019; 13(10): e0007733. https://doi.org/10.1371/journal.pntd.0007733

Wu, Brian (2 May 2015). "Ebola Can Be Transmitted Through Sex". Science Times. Archived from the original on 2 May 2015. Retrieved 3 May 2015.

Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses. 2012 Sep;4(9):1668-86. doi: 10.3390/v4091668. Epub 2012 Sep 21. Review. PubMed PMID: 23170178; PubMed Central PMCID: PMC3499825.[PubMed].

Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011 Mar 5;377(9768):849-62. doi: 10.1016/S0140-6736(10)60667-8. Review. PubMed PMID: 21084112; PubMed Central PMCID: PMC3406178.[PubMed]

Singh SK, Ruzek D, eds. (2014). Viral hemorrhagic fevers. Boca Raton: CRC Press, Taylor & Francis Group. p. 444. ISBN 9781439884294. Archived from the original on 29 April 2016.

"What is Contact Tracing?" (PDF). Centers for Disease Control and Prevention (CDC). Archived (PDF) from the original on 12 September 2014. Retrieved 15 September 2014.

"As Ebola outbreak rages, vaccine is 97.5% effective, protecting over 90K people". 16 April 2019.

"FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus" (Press release). 17 September 2019. Retrieved 17 September 2019 – via Business Wire.

Hoenen T, Groseth A, Feldmann H. Current ebola vaccines. Expert Opin Biol Ther. 2012 Jul;12(7):859-72. doi: 10.1517/14712598.2012.685152. Epub 2012 May 5. Review. PubMed PMID: 22559078; PubMed Central PMCID: PMC3422127.[PubMed]

Available on https://www.statnews.com/2019/10/18/with-european-backing-the-world-is-on-the-brink-of-the-first-approved-ebola-vaccine/?utm_source=STAT+Newsletters&utm_campaign=9de79e8b15-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-9de79e8b15-151218197 Last assessed on 19/11/2019

Most read articles by the same author(s)

1 2 > >>